SCYX 7158 clinical trials
Also written Acoziborole and SCYX-7158.
How each study uses SCYX 7158 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SCYX 7158 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 7
Drugs for Neglected Diseases (6) · Institute of Tropical Medicine, Belgium (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test SCYX 7158, phase 3 first.
- Dec 2026Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT)Phase 3 · Drugs for Neglected Diseases
- Dec 2026Stop Transmission of Gambiense Human African TrypanosomiasisPhase 3 · Institute of Tropical Medicine, Belgium
Studies
Open first, then newest update. How each study uses SCYX 7158 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Stop Transmission of Gambiense Human African TrypanosomiasisRecruitingPhase 3Institute of Tropical Medicine, BelgiumNCT07789743Written as Acoziborole
- Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT)Not yet recruitingPhase 3Drugs for Neglected DiseasesNCT06356974Written as Treatment of seropositive individuals (positive serology test, but parasitology not confirmed)
- Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric PatientsCompletedPhase 2/3Drugs for Neglected DiseasesNCT05433350Written as Acoziborole
- Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. GambienseCompletedPhase 2/3Drugs for Neglected DiseasesNCT03087955Written as Acoziborole
- Safety and Tolerability Study of Acoziborole in g-HAT Seropositive SubjectsCompletedPhase 2/3Drugs for Neglected DiseasesNCT05256017Written as Acoziborole
- DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and DextromethorphanCompletedPhase 1Drugs for Neglected DiseasesNCT05947604Written as Acoziborole
- Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158CompletedPhase 1Drugs for Neglected DiseasesNCT01533961Written as SCYX-7158